Stockreport

argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition

argenx SE - American Depositary Shares  (ARGX) 
PDF Regulated information – Inside information 92% overall response rate with durability up to 14.4 months in ongoing analysis of Phase 1/2 trial  Updated results [Read more]